...

Rising Demand for Women’s Health APIs in Emerging Markets (2026)

For many, the phrase “women’s health” becomes synonymous with contraception.

However, for those in business development, procurement, or portfolio management, “women’s health” encompasses a far broader scope.

The scope includes maternal health to prevent postpartum haemorrhage, as well as conditions including anaemia, osteoporosis, cancer, and other gynaecological conditions.

There are different product needs across these conditions and at varying levels.

Rapidly increasing demand for women’s health conditions is occurring in the same regions where emerging healthcare systems are developing.

These regions provide the best opportunities for business growth.

Supplying women’s health products presents challenges, including unstable cold chains and variations in tenders and regulations.

This article provides an analysis of the primary markets for women’s health APIs and women’s health formulations, and the barriers to supply.

Understanding these barriers allows companies to strategically align their business for greater opportunity in women’s health products.

The Demand Is Real and Structural, Not Cyclical

The Women’s health market is defined and segmented differently by various sources.

According to IMARC, Fortune Business Insights, and Grand View Research, the global women’s health market will reach between $44.1 billion[1] and $56.85 billion[2] by 2025.

the demand is real and structural not cyclical

The market at a glance

Estimates show the market will grow between 5.1%[3] and 6.31%[4] each year.

Precedence Research expects hormonal therapies will be the largest drug class in the women’s health market, and The Business Research Company expects the market in Asia will grow the fastest.

What is actually driving it

what is actually driving it

The causes are more demographic than trend-related:

  • Reproductive-age populations: 1.6 billion women of reproductive age[5] are in the developing world.

  • Ageing: There are approximately 1 billion women worldwide[6] who have gone through menopause, creating a demand for hormone therapy and other products related to bone health and oncology.

  • Access and policy: Improving access and policies related to women’s health could improve the economic status of women in the world and could increase the global gross domestic product by $1 trillion by the year 2040.

Two considerations are made for portfolio planning.

First, the demand base encompasses reproductive, maternal, and post-menopausal populations; thus, it is not limited to a single trend in the demand for a specific product.

Second, product demand varies by geography, reflecting differences in the speed of reimbursement by insurance and the timing of procurement by the public sector.

Women’s Health Is Far Larger Than Family Planning

Contraceptives comprise 28.17%[7] (as of 2021) market,, which means approximately 70% of the market consists of other women’s health products.

Women’s health encompasses several therapeutic areas. 

women’s health is far larger than family planning

Developing products for just one of these areas is less competitive than developing a product for a variety of areas.

Of the several areas, some require more advanced pharmaceutical APIs and, if developed, would earn a high profit margin. 

Some pillars are high-volume and price-sensitive; others, such as hormonal oncology and hormone therapy, reward technical capability and documentation.

A portfolio that encompasses several therapeutic areas is preferred.

PillarRepresentative moleculesDemand driver
Reproductive health and contraceptionLevonorgestrel; oral and injectable contraceptive APIsUnmet need; family-planning programmes
Maternal healthOxytocin, misoprostol, carbetocin, tranexamic acid, iron–folic acidPostpartum haemorrhage; anaemia in pregnancy
Menopause and HRTEstradiol, conjugated estrogens, progesteronesAgeing populations
Bone healthAlendronate, risedronate, zoledronic acid, raloxifenePost-menopausal osteoporosis
Hormonal oncologyTamoxifen, letrozole, anastrozoleBreast cancer incidence; oncology access
Gynaecological conditionsPCOS, endometriosis, fibroid therapiesRising diagnosis rates
Female-specific infectionsAntifungals; agents for bacterial vaginosis, UTIsHigh prevalence
Anaemia and micronutrientsIron salts, folic acid, ferric carboxymaltoseHigh anaemia prevalence

Why the Need Goes Unmet and What That Costs

Mothers still die of preventable haemorrhage

why the need goes unmet and what that costs

PPH is the largest contributor to the global maternal health crisis.

It is estimated that 14 million women experience PPH annually, and over 70,000 women die from it.[8]

It is a particular crisis for women in low- and lower-middle-income countries.

PPH accounts for approximately 99%[9] of postpartum haemorrhage (PPH) -related maternal mortalities in the low- and middle- income countries (LMICs).

The World Health Organization (WHO) recommends the use of uterotonics, mainly oxytocin and misoprostol, for prevention and treatment of PPH.

Carbetocin is heat stable and may prove to be useful in contexts where the cold chain is not functional.

According to a study published in PMC, heat stable carbetocin maintained peptide purity for a period of three years at 30°C and 75% relative humidity.

Contraceptive need outpaces supply

Contraception. In 2017, Guttmacher reported that approximately 214 million women[10] in developing countries did not have access to modern contraceptives.

In the process, they put themselves at risk of unplanned pregnancy. The report serves as a historical benchmark, as figures always vary.

Female cancers are rising where care is scarcest

High-income nations tend to have higher rates of female cancer incidence, while lower-income nations have higher female cancer mortality rates.

female cancers are rising where care is scarcest

Approximately 70% of female[11] cancer deaths occur in low-income nations.

In high-HDI (high Human Development Index) nations, about 1 in 71 women die from breast cancer, while 1 in 27 women in low-HDI nations die from breast cancer.

About 94% of cervical cancer[12] deaths occur in low- and middle-income countries.

The targets in the WHO’s 90-70-90 initiative aim to achieve the elimination of cervical cancer.

The primary barrier to eliminating these female cancers is the availability of essential health interventions.

Often, the interventions required to close these gaps have already been developed.

Mapping the Opportunity: Where Demand Concentrates

Route to market varies by segment. Some demand relies on donor funding and tenders.

Some are public. The rest is commercial.

SegmentDemand signalDominant channel(s)
ContraceptivesRecurring; largest single applicationDonor (UNFPA) + public + growing private
Maternal commoditiesHigh, life-savingPublic procurement + donor programmes
Hormonal oncologyRising with incidence and accessPublic + private hospitals
Bone health and HRTRising with ageingIncreasingly commercial/retail
Gynaecological conditionsRising with diagnosisCommercial/retail
Anaemia and micronutrientsBroad, high-volumePublic + OTC + programmes

There is a certain standard of quality required of donors.

A 2006 USAID-sponsored report noted UNFPA as a major buyer of hormonal contraceptives and noted Indian manufacturers as strong performers in international tenders, in part, due to strict quality standards.

The authors noted the importance of having a strong quality system for donor funds, but noted that for commercial funds, having a strong distribution system is more important.

The Same Category, Very Different Markets

The Guttmacher Institute finds that when looking at contraceptive needs across the emerging markets, unmet need for modern contraception is the highest in Sub-Saharan Africa (21%), with the highest absolute number (approximately 70 million women) in Southern Asia.

RegionWhere demand concentratesMarket character
Sub-Saharan AfricaMaternal health, contraception, cervical cancer, anaemiaLargely donor-funded and public; tender-driven
South AsiaHigh-volume maternal health, anaemia, contraception; rising oncology and HRTLarge public programmes plus growing private
Southeast AsiaContraception, HRT, oncology, gynaecological conditionsMixed public/private; rising middle class
Latin AmericaAgeing-driven: HRT, osteoporosis, breast and cervical cancerMore commercial; stronger private and insurance markets
MENAGrowing across segmentsMostly commercial; regulatory and cultural specificity

Reasons for the lack of reproductive product access in some regions are regulatory and cultural, not values-related.

India’s Supply Position in Women’s Health

India provides approximately 20% of the world’s generic medicines and has the second-highest number of US FDA-approved facilities, next to the US.

India’s pharmaceutical manufacturing supplies the women’s health supply chain with hormonal contraceptives. 

india’s supply position in women’s health

Contraceptives are manufactured for institutional tenders such as the ones issued by the US Agency for International Development (USAID).

Manufacturers in India are moving up the value chain. Currently, India has less than 8% of the global market share for APIs, and as a result, most local manufacturers produce high-potency APIs. 

Many pharmaceutical companies have begun constructing High Potency API Suites to manufacture compounds that have occupational exposure limits of less than 1 μg/m³.[13]

India is able to produce a broader range of pharmaceuticals. 

Customers will need to determine the containment, quality, and regulatory standards of the local pharmaceutical manufacturers to assess if they are able to supply the desired pharmaceuticals.

The Supply Reality: Why This Category Is Harder to Serve

Being a generalist with an interest in women’s health is risky.

There are four key realities that determine who can serve this area well, and they tend to favour the more technical of us.

RealityWhat it meansBuyer implication
Hormonal API containmentPotent, low-dose molecules need production facilities separate from other pharmaceutical products and controlled environmentsVerify dedicated hormonal APIs capacity, not shared lines
Cold chain and stabilityOxytocin loses potency without refrigeration; heat-stable carbetocin stays stable up to 30°C for at least three yearsConfirm stability data for the destination climate
Quality and tender barriersDonor and public tenders expect WHO-GMP, prequalification-grade quality and full stability documentationPrioritise WHO-PQ/SRA-grade suppliers; model total cost
Demand heterogeneityChannel, funding and culture differ by regionMatch product and channel to the market

FP Analytics found that when foreign aid is cut, funding for reproductive health and rights is drastically reduced.

Because of this, there is financial instability for donor-funded programs, and markets that have shifted programs to national budgets are likely more stable.

What a Capable Women’s Health Supply Partner Looks Like

Buyers need to measure API manufacturers and pharmaceutical manufacturers against the above criteria and determine whether they have verifiable GMPs, the necessary capability to produce the given molecule (and containment, if required), quality and stability, regulatory readiness and prequalification, adequate portfolio, and the ability to produce for donor, public and commercial clients.

According to its public documents, Actiza manufactures more than 25 dosage forms under WHO-GMP.

Actiza produces APIs and pharmaceutical, intermediates, and it has over 550 ready-to-use dossiers.

Suppliers that respond to specific molecule requests generally answer in more detail and are better to work with.

FAQ

Q1. What counts as a women’s health API?

Any active pharmaceutical ingredient (API) associated with conditions that are predominantly male- or female-related, for example, various types of hormones, uterotonics, misoprostol, bone resorptive agents, hormonal oncological agents, iron and folic acid.

Q2. Why is demand for women’s health products rising in emerging markets?

Improvements in diagnosis and treatment, and an increase in public awareness and policy, have led to a sustained and increasing demand in this area.

Q3. Which women’s health segment is the largest?

According to Grand View Research, contraceptives accounted for $19.33 billion or 28.17% of the market in 2021. Additionally, according to Precedence Research, hormonal drugs accounted for the largest market share in 2020.

Q4. Why are hormonal APIs harder to manufacture?

Hormonal APIs are difficult to produce because of their high potency and low dosage forms. Cross-contamination should be avoided, as exposure limits for some hormonal drugs are as low as 1 μg/m³.

Q5. Are women’s health markets in developing countries donor-funded or commercial?

A combination of both. Contraceptives and maternal health products are donor- and government-funded, while hormonal products and gynaecological products are more commercial.

Conclusion

The demand for women’s health medicines in the emerging markets is one of the most stable and consistently strong market opportunities in the pharmaceutical industry.

The global market scope for these medicines is wider and the volume larger than for medicines to prevent and treat family planning.

Women’s health medicines span products for fertility control, contraception, pregnancy, childbirth and post-childbirth health, including breast cancer and menopause.

Sustainable access to these women’s health medicines requires pharmaceutical companies to have the hormonal formulation capability and stability of medicines during transport and storage in developing countries with a varying climate.

If you are creating a women’s health medicines portfolio or wish to evaluate a specific women’s health medicine, contact Actiza.

  1. https://www.imarcgroup.com/womens-health-market
  2. https://www.fortunebusinessinsights.com/industry-reports/women-s-health-market-101847
  3. https://www.grandviewresearch.com/industry-analysis/womens-health-market
  4. https://www.fortunebusinessinsights.com/industry-reports/women-s-health-market-101847
  5. https://www.guttmacher.org/fact-sheet/adding-it-up-contraception-mnh-2017
  6. https://fpanalytics.foreignpolicy.com/2025/08/28/innovation-investment-womens-health/
  7. https://www.grandviewresearch.com/industry-analysis/womens-health-market
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC12145113/
  9. https://www.who.int/news/item/20-12-2018-who-updates-guidance-to-help-healthcare-workers-prevent-postpartum-haemorrhage
  10. https://www.guttmacher.org/fact-sheet/adding-it-up-contraception-mnh-2017
  11. https://www.uicc.org/news-and-updates/news/globocan-2022-latest-global-cancer-data-shows-rising-incidence-and-stark
  12. https://www.who.int/initiatives/cervical-cancer-elimination-initiative
  13. https://www.drugpatentwatch.com/blog/indias-growing-importance-in-generic-drug-api-manufacturing/

About the Author

Nilesh Mendpara MD of ACTIZA PHARMA Profile Image
Nilesh Mendpara

Nilesh Mendpara is the Managing Director of Actiza Pharmaceutical PVT. LTD., based in Surat, Gujarat, India. With over 10 years of experience in the pharmaceutical industry, Nilesh is passionate about spreading pharmaceutical knowledge and staying ahead of industry trends. He holds a Master of Pharmacy (Distinction) and a Bachelor's in Pharmacy from Rajiv Gandhi University of Health Sciences. Under his leadership, Actiza Pharmaceutical aims to be the most trusted partner for pharmaceutical exports worldwide, ensuring the highest standards of quality and safety. Connect with Nilesh to explore opportunities in advancing global healthcare.

[Read more]
Request A Call Back

We are a 100% export-oriented company and do not engage in domestic sales within India.